Heart disease (Hagerstown, Md.)最新文献_第9页

Does the serum cardiac troponin I level increase with stress test-induced myocardial ischemia? 血清心肌肌钙蛋白I水平是否随应激试验引起的心肌缺血而升高?

Heart disease (Hagerstown, Md.) Pub Date : 2002-07-01 DOI: 10.1097/00132580-200207000-00004

N. Choragudi, W. Aronow, A. Prakash, S. K. Kurup, S. Chiaramida, R. Lucariello

{"title":"Does the serum cardiac troponin I level increase with stress test-induced myocardial ischemia?","authors":"N. Choragudi, W. Aronow, A. Prakash, S. K. Kurup, S. Chiaramida, R. Lucariello","doi":"10.1097/00132580-200207000-00004","DOIUrl":"https://doi.org/10.1097/00132580-200207000-00004","url":null,"abstract":"To evaluate the sensitivity of the serum cardiac troponin I level in detecting stress test-induced myocardial ischemia, the authors conducted a prospective study including patients admitted for chest pain to the telemetry floor of Our Lady of Mercy Medical Center at Bronx, NY. Consecutive 134 telemetry patients that agreed to participate in this study were included. All of these patients had a nuclear stress test and were divided into various groups based on the prestress test probability of having coronary artery disease. To assess serum cardiac troponin I levels, blood samples were drawn before and after stress testing and compared with the stress test results. Overall, 30 patients (22%) had reversible perfusion defects on stress images, and none (0%) had increased serum cardiac troponin I levels. One patient of 18 patients (6%) in group C with negative stress test results had an elevated serum cardiac troponin I level after the stress test, but none of group A or group B patients had elevated troponin I levels. These data show that serum cardiac troponin I levels do not increase with stress test-induced myocardial ischemia.","PeriodicalId":83724,"journal":{"name":"Heart disease (Hagerstown, Md.)","volume":"4 4 1","pages":"216-9"},"PeriodicalIF":0.0,"publicationDate":"2002-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00132580-200207000-00004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61588519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

The hemodynamics of erection and the pharmacotherapies of erectile dysfunction. 勃起的血流动力学与勃起功能障碍的药物治疗。

Heart disease (Hagerstown, Md.) Pub Date : 2002-07-01 DOI: 10.1097/00132580-200207000-00008

A. Melman, G. Christ

{"title":"The hemodynamics of erection and the pharmacotherapies of erectile dysfunction.","authors":"A. Melman, G. Christ","doi":"10.1097/00132580-200207000-00008","DOIUrl":"https://doi.org/10.1097/00132580-200207000-00008","url":null,"abstract":"The past few years have been witness to a sea of change in understanding the diagnosis and treatment of erectile dysfunction. In the wake of Viagra, effective orally administered therapies are now the expected gold standard. Currently available therapies include both peripherally (at the level of the penis) and centrally (brain, e.g., hypothalamic nuclei) acting compounds. When all modes of pharmacotherapy are considered, ranging from oral, to topical, to intraurethral, to intracavernous injection, it is clear that the vast majority of men with mild to moderate erectile dysfunction can now be effectively treated. However, all forms of pharmacotherapy have the lowest efficacy and greatest side effect profiles (including cardiovascular events) in the patients that need the therapy most, that is, those with relatively severe and longstanding erectile dysfunction. The newer generation of pharmacotherapies, which will likely include gene therapy techniques as well, will therefore have to target this latter group. Improved mechanism-based, perhaps patient-specific therapies are foreseen that will dramatically increase the number of patients seeking treatment, as well as the quality of their lives.","PeriodicalId":83724,"journal":{"name":"Heart disease (Hagerstown, Md.)","volume":"4 4 1","pages":"252-64"},"PeriodicalIF":0.0,"publicationDate":"2002-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00132580-200207000-00008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61588607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Stem cell therapy for myocardial regeneration: the future is now. 干细胞治疗心肌再生:未来就是现在。

Heart disease (Hagerstown, Md.) Pub Date : 2002-07-01 DOI: 10.1097/00132580-200207000-00001

W. Frishman, P. Anversa

引用次数: 4

Recent dietary guidelines to prevent and treat cardiovascular disease, diabetes, and obesity. 最近的饮食指南预防和治疗心血管疾病、糖尿病和肥胖症。

Heart disease (Hagerstown, Md.) Pub Date : 2002-07-01 DOI: 10.1097/00132580-200207000-00005

J. Wylie-Rosett, Y. Mossavar-Rahmani, K. Gans

{"title":"Recent dietary guidelines to prevent and treat cardiovascular disease, diabetes, and obesity.","authors":"J. Wylie-Rosett, Y. Mossavar-Rahmani, K. Gans","doi":"10.1097/00132580-200207000-00005","DOIUrl":"https://doi.org/10.1097/00132580-200207000-00005","url":null,"abstract":"Nutrition guidelines are emphasizing dietary patterns as primary and secondary prevention trials provide increasing evidence of the importance of lifestyle changes to prevent/control cardiovascular disease (CVD) risk factors such as diabetes and hypertension. Despite the increasing evidence that weight loss and modified dietary patterns are effective, there is considerable debate about the level of carbohydrate that will be most beneficial. Epidemiologic studies indicate that certain ethnic and racial minority groups have increased CVD risk with higher rates of obesity, hypertension, diabetes, and stroke. Immigrant and Native American populations have had a dramatic rise in obesity, diabetes, and ultimately CVD with acculturation, accompanied by a higher fat intake and decreased physical activity. Culturally tailored intervention approaches are being used to reduce risk. The lack of third-party payment still limits the availability of nutrition services. However, medical nutrition therapy is covered by Medicare for diabetes and pending legislation will extend coverage to CVD. Medical education researchers have developed tools such as the WAVE (Weight, Activity, Variety and Excess) pocket guide as a quick method to facilitate addressing referral for medical nutrition therapy that can be readily incorporated into practice settings.","PeriodicalId":83724,"journal":{"name":"Heart disease (Hagerstown, Md.)","volume":"4 4 1","pages":"220-30"},"PeriodicalIF":0.0,"publicationDate":"2002-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00132580-200207000-00005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61588563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Intraoral topical nonsteroidal antiinflammatory drug application for headache prevention. 局部口服非甾体类抗炎药在预防头痛中的应用。

Heart disease (Hagerstown, Md.) Pub Date : 2002-07-01 DOI: 10.1097/00132580-200207000-00003

M. Friedman, S. Peterson, W. Frishman, C. Behar

{"title":"Intraoral topical nonsteroidal antiinflammatory drug application for headache prevention.","authors":"M. Friedman, S. Peterson, W. Frishman, C. Behar","doi":"10.1097/00132580-200207000-00003","DOIUrl":"https://doi.org/10.1097/00132580-200207000-00003","url":null,"abstract":"Recent evidence suggests an association between migraine and tension-type headache and local inflammation occurring in a maxillary nerve segment. This study was designed to evaluate the efficacy of topical ketoprofen for the prevention of migraine, tension-type, and posttraumatic headache. Patients with a headache frequency of at least once a week recorded the frequency, severity, duration, and type of headache for 60 days. After 30 days, patients applied the medication daily for the next 30 days to the periapical area of the maxillary molars on the symptomatic side(s). Headache medications and analgesics were permitted, as needed. Headache burden was defined as the average intensity of each headache (0-10 scale) multiplied by its duration, in hours. The average monthly headache burden score for the 20 patients enrolled in this study decreased from 454.8 (30-day baseline) to 86.5 P < 0.001 during the 30-day treatment phase. Analgesic and headache medication intake were significantly reduced from baseline during the treatment phase, and side effects were minimal.","PeriodicalId":83724,"journal":{"name":"Heart disease (Hagerstown, Md.)","volume":"4 4 1","pages":"212-5"},"PeriodicalIF":0.0,"publicationDate":"2002-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00132580-200207000-00003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61588507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Challenges in dyslipidemia. 血脂异常的挑战。

Heart disease (Hagerstown, Md.) Pub Date : 2002-05-01 DOI: 10.1097/00132580-200205000-00002

H. Burke

引用次数: 0

Reduction of coronary events with aspirin in older patients with prior myocardial infarction treated with and without statins. 既往有心肌梗死的老年患者服用阿司匹林可减少冠状动脉事件。

Heart disease (Hagerstown, Md.) Pub Date : 2002-05-01 DOI: 10.1097/00132580-200205000-00005

W. Aronow, C. Ahn

引用次数: 34

Anesthetic considerations in the patient with a heart transplant. 心脏移植患者的麻醉注意事项。

Heart disease (Hagerstown, Md.) Pub Date : 2002-05-01 DOI: 10.1097/00132580-200205000-00010

Nishan Ashary, A. Kaye, Amr Hegazi, Elizabeth A. M. Frost

引用次数: 15

Radiofrequency catheter ablation of a left lateral accessory pathway in a patient with persistent left superior vena cava. 持续性左上腔静脉左外侧副通路的射频导管消融。

Heart disease (Hagerstown, Md.) Pub Date : 2002-05-01 DOI: 10.1097/00132580-200205000-00006

H. Kurşaklioğlu, S. Kose, C. Barçın, A. Iyisoy, E. Işik, E. Demirtaş

引用次数: 8

Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs. 单芥碱对大鼠肺内皮型一氧化氮合酶表达及巯基水平的影响。

Heart disease (Hagerstown, Md.) Pub Date : 2002-05-01 DOI: 10.1097/00132580-200205000-00004

R. Mathew, N. Yuan, L. Rosenfeld, M. Gewitz, Ashok Kumar

{"title":"Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs.","authors":"R. Mathew, N. Yuan, L. Rosenfeld, M. Gewitz, Ashok Kumar","doi":"10.1097/00132580-200205000-00004","DOIUrl":"https://doi.org/10.1097/00132580-200205000-00004","url":null,"abstract":"The nitric oxide-cyclic guanosine monophosphate signal-transduction mechanism plays a key role in the regulation of vascular tone and structure. Monocrotaline-induced pulmonary hypertension is associated with low bioavailability of nitric oxide. To characterize the mechanism(s) involved in this dysfunction, rats received a single subcutaneous injection of monocrotaline, normal saline (control), or monocrotaline plus daily L-arginine, a precursor of nitric oxide, in drinking water. Pulmonary artery pressure and right ventricular hypertrophy were assessed 2 weeks later. In addition, the authors evaluated the expression of endothelial nitric oxide synthase messenger RNA, endothelial nitric oxide synthase protein, cyclic guanosine monophosphate, and sulfhydryl levels in the lungs. Sulfhydryls are needed for the dynamic modulation of soluble guanylate cyclase by nitric oxide, which results in cyclic guanosine monophosphate formation. L-arginine treatment did not attenuate monocrotaline-induced pulmonary hypertension or right ventricular hypertrophy. Monocrotaline did not alter the expression of endothelial nitric oxide synthase messenger RNA or endothelial nitric oxide synthase protein in the lungs. Protein-bound sulfhydryls (28 +/- 5 vs. 75 +/- 16 pmol/microg protein) and cyclic guanosine monophosphate (0.63 +/- 0.05 vs. 1.06 +/- 0.017 pmol/microg protein) levels in the monocrotaline group were significantly low compared with controls. The low sulfhydryl levels, an indicator of oxidant stress, may account for the impaired availability of bioactive nitric oxide and low cyclic guanosine monophosphate levels. These results suggest that oxidative stress may, in part, contribute to the pathogenesis of pulmonary hypertension in the monocrotaline model.","PeriodicalId":83724,"journal":{"name":"Heart disease (Hagerstown, Md.)","volume":"4 3 1","pages":"152-8"},"PeriodicalIF":0.0,"publicationDate":"2002-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00132580-200205000-00004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61588748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 30